Serious adverse events
|
Ramipril |
LCZ696 |
Total subjects affected by serious adverse events
|
|
|
subjects affected / exposed
|
1126 / 2816 (39.99%) |
1146 / 2820 (40.64%) |
number of deaths (all causes)
|
244 |
220 |
number of deaths resulting from adverse events
|
5 |
4 |
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
|
|
|
Adenocarcinoma
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Adenocarcinoma of colon
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Adenocarcinoma pancreas
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Anaplastic meningioma
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
B-cell lymphoma
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
B-cell small lymphocytic lymphoma
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
B-cell unclassifiable lymphoma low grade
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Basal cell carcinoma
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
4 / 2820 (0.14%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Benign duodenal neoplasm
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Bladder neoplasm
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Bladder cancer
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
4 / 2820 (0.14%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Bladder transitional cell carcinoma
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Breast cancer
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Bowen's disease
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Breast cancer stage II
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Bronchial carcinoma
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cholangiocarcinoma
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Chronic myeloid leukaemia
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Chronic lymphocytic leukaemia
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Colon cancer
|
|
|
subjects affected / exposed
|
5 / 2816 (0.18%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Clear cell renal cell carcinoma
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Colon neoplasm
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Colorectal cancer
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Colorectal adenocarcinoma
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Endometrial cancer
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gallbladder adenosquamous carcinoma
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Gallbladder cancer
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastric cancer
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastric neoplasm
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastrointestinal carcinoma
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastrointestinal neoplasm
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Glioblastoma
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Hepatocellular carcinoma
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
Hepatic cancer
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
Haemangioma of liver
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypopharyngeal cancer
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Infected neoplasm
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Keratoacanthoma
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Laryngeal squamous cell carcinoma
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Laryngeal cancer
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lip squamous cell carcinoma
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lung adenocarcinoma
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lung cancer metastatic
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
Lung neoplasm
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
Lung neoplasm malignant
|
|
|
subjects affected / exposed
|
5 / 2816 (0.18%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 3 |
0 / 1 |
Lung squamous cell carcinoma metastatic
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Lymphangiosis carcinomatosa
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Malignant melanoma
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Malignant peritoneal neoplasm
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Malignant neoplasm of pleura
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Marginal zone lymphoma
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Meningioma
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Metastases to liver
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Metastases to lymph nodes
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Metastatic malignant melanoma
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Metastasis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 2 |
Metastatic neoplasm
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Myeloproliferative neoplasm
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Monoclonal gammopathy
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Myxoid liposarcoma
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Neoplasm malignant
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Neoplasm progression
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Neuroendocrine carcinoma
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Non-small cell lung cancer
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Oesophageal carcinoma
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Oropharyngeal cancer
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pancreatic carcinoma
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 3 |
Papillary cystadenoma lymphomatosum
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pleural mesothelioma malignant
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Prostate cancer
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
5 / 2820 (0.18%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Prostate cancer metastatic
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Rectal adenocarcinoma
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Rectal cancer
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
4 / 2820 (0.14%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Rectal neoplasm
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Renal cancer metastatic
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Squamous cell carcinoma
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Squamous cell carcinoma of skin
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Testicular neoplasm
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Squamous cell carcinoma of the parotid gland
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Transitional cell cancer of the renal pelvis and ureter
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Transitional cell carcinoma
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Tumour haemorrhage
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Vulval cancer
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Vascular disorders
|
|
|
Aneurysm ruptured
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Angiodysplasia
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Aortic aneurysm
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Aortic dissection
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Aortic stenosis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Aortic occlusion
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Arterial haemorrhage
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Arterial occlusive disease
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Arterial stenosis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Arterial thrombosis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Arteriosclerosis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Circulatory collapse
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
1 / 3 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Brachiocephalic arteriosclerosis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Deep vein thrombosis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Distributive shock
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Embolism arterial
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Extremity necrosis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
4 / 2820 (0.14%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Femoral artery aneurysm
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Haematoma
|
|
|
subjects affected / exposed
|
7 / 2816 (0.25%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 7 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypertension
|
|
|
subjects affected / exposed
|
9 / 2816 (0.32%) |
6 / 2820 (0.21%) |
occurrences causally related to treatment / all
|
0 / 10 |
0 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypertensive crisis
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
4 / 2820 (0.14%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypertensive emergency
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypertensive urgency
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypotension
|
|
|
subjects affected / exposed
|
15 / 2816 (0.53%) |
37 / 2820 (1.31%) |
occurrences causally related to treatment / all
|
7 / 16 |
23 / 42 |
deaths causally related to treatment / all
|
1 / 1 |
0 / 0 |
Hypovolaemic shock
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Iliac artery stenosis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Iliac artery occlusion
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Intermittent claudication
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ischaemic limb pain
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Jugular vein thrombosis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Obstructive shock
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Orthostatic hypotension
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
5 / 2820 (0.18%) |
occurrences causally related to treatment / all
|
2 / 3 |
3 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Peripheral arterial occlusive disease
|
|
|
subjects affected / exposed
|
9 / 2816 (0.32%) |
7 / 2820 (0.25%) |
occurrences causally related to treatment / all
|
0 / 9 |
0 / 10 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Peripheral artery aneurysm
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Peripheral artery occlusion
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Peripheral artery stenosis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Peripheral artery thrombosis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Peripheral vascular disorder
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
4 / 2820 (0.14%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Peripheral ischaemia
|
|
|
subjects affected / exposed
|
9 / 2816 (0.32%) |
6 / 2820 (0.21%) |
occurrences causally related to treatment / all
|
0 / 10 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Phlebitis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Reperfusion injury
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Subclavian artery occlusion
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Thrombophlebitis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Thrombophlebitis superficial
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Venous aneurysm
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Venous haemorrhage
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Surgical and medical procedures
|
|
|
Cardiac pacemaker insertion
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Transcatheter aortic valve implantation
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pregnancy, puerperium and perinatal conditions
|
|
|
Hyperemesis gravidarum
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pre-eclampsia
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
General disorders and administration site conditions
|
|
|
Adverse event
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cardiac death
|
|
|
subjects affected / exposed
|
4 / 2816 (0.14%) |
5 / 2820 (0.18%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 4 |
0 / 5 |
Chest discomfort
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Asthenia
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
1 / 5 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Death
|
|
|
subjects affected / exposed
|
31 / 2816 (1.10%) |
27 / 2820 (0.96%) |
occurrences causally related to treatment / all
|
0 / 31 |
2 / 27 |
deaths causally related to treatment / all
|
0 / 31 |
2 / 27 |
Chest pain
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Complication associated with device
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Disease progression
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Drowning
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
General physical health deterioration
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Exercise tolerance decreased
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Fatigue
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
1 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypothermia
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Generalised oedema
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Impaired healing
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Malaise
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Multiple organ dysfunction syndrome
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 3 |
Necrosis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Non-cardiac chest pain
|
|
|
subjects affected / exposed
|
66 / 2816 (2.34%) |
54 / 2820 (1.91%) |
occurrences causally related to treatment / all
|
0 / 70 |
0 / 64 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Oedema peripheral
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Polyp
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pyrexia
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
7 / 2820 (0.25%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 8 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Sudden cardiac death
|
|
|
subjects affected / exposed
|
14 / 2816 (0.50%) |
10 / 2820 (0.35%) |
occurrences causally related to treatment / all
|
0 / 14 |
0 / 10 |
deaths causally related to treatment / all
|
0 / 14 |
0 / 10 |
Sudden death
|
|
|
subjects affected / exposed
|
8 / 2816 (0.28%) |
9 / 2820 (0.32%) |
occurrences causally related to treatment / all
|
0 / 8 |
0 / 9 |
deaths causally related to treatment / all
|
0 / 8 |
0 / 9 |
Surgical failure
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ulcer haemorrhage
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Unevaluable event
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Vascular stent stenosis
|
|
|
subjects affected / exposed
|
5 / 2816 (0.18%) |
5 / 2820 (0.18%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Vascular stent thrombosis
|
|
|
subjects affected / exposed
|
7 / 2816 (0.25%) |
7 / 2820 (0.25%) |
occurrences causally related to treatment / all
|
0 / 7 |
0 / 8 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 2 |
Immune system disorders
|
|
|
Anaphylactic shock
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Contrast media allergy
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Drug hypersensitivity
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Social circumstances
|
|
|
Immobile
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Alcoholic
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Imprisonment
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Reproductive system and breast disorders
|
|
|
Benign prostatic hyperplasia
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
4 / 2820 (0.14%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Breast necrosis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Breast pain
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cervical polyp
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Female genital tract fistula
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hysterocele
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ovarian cyst
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Postmenopausal haemorrhage
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Prostatomegaly
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Scrotal oedema
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Uterine haemorrhage
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Uterine polyp
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Uterine prolapse
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Respiratory, thoracic and mediastinal disorders
|
|
|
Acute pulmonary oedema
|
|
|
subjects affected / exposed
|
13 / 2816 (0.46%) |
19 / 2820 (0.67%) |
occurrences causally related to treatment / all
|
0 / 17 |
0 / 24 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 3 |
Acute respiratory failure
|
|
|
subjects affected / exposed
|
5 / 2816 (0.18%) |
7 / 2820 (0.25%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 3 |
0 / 3 |
Aspiration
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Asphyxia
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Asthma
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Atelectasis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Chronic obstructive pulmonary disease
|
|
|
subjects affected / exposed
|
13 / 2816 (0.46%) |
14 / 2820 (0.50%) |
occurrences causally related to treatment / all
|
0 / 23 |
0 / 19 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Dyspnoea
|
|
|
subjects affected / exposed
|
28 / 2816 (0.99%) |
34 / 2820 (1.21%) |
occurrences causally related to treatment / all
|
6 / 34 |
0 / 38 |
deaths causally related to treatment / all
|
0 / 3 |
0 / 0 |
Cough
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
2 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Dyspnoea at rest
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Dyspnoea paroxysmal nocturnal
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Dyspnoea exertional
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
6 / 2820 (0.21%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Epistaxis
|
|
|
subjects affected / exposed
|
7 / 2816 (0.25%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 7 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Haemoptysis
|
|
|
subjects affected / exposed
|
4 / 2816 (0.14%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
Haemothorax
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hydrothorax
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
4 / 2820 (0.14%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypoxia
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Interstitial lung disease
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lung consolidation
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lung disorder
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pleural effusion
|
|
|
subjects affected / exposed
|
6 / 2816 (0.21%) |
4 / 2820 (0.14%) |
occurrences causally related to treatment / all
|
0 / 9 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Painful respiration
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Orthopnoea
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pneumonia aspiration
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pneumonitis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pneumothorax
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pulmonary alveolar haemorrhage
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pulmonary artery thrombosis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pulmonary congestion
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Pulmonary embolism
|
|
|
subjects affected / exposed
|
5 / 2816 (0.18%) |
8 / 2820 (0.28%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 8 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pulmonary hypertension
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pulmonary mass
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pulmonary oedema
|
|
|
subjects affected / exposed
|
13 / 2816 (0.46%) |
12 / 2820 (0.43%) |
occurrences causally related to treatment / all
|
0 / 17 |
0 / 12 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 2 |
Pulmonary pain
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Respiratory distress
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Tracheal stenosis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Sleep apnoea syndrome
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Respiratory failure
|
|
|
subjects affected / exposed
|
11 / 2816 (0.39%) |
11 / 2820 (0.39%) |
occurrences causally related to treatment / all
|
0 / 12 |
0 / 12 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 1 |
Psychiatric disorders
|
|
|
Anxiety
|
|
|
subjects affected / exposed
|
5 / 2816 (0.18%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Completed suicide
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Confusional state
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Delirium
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Delusion
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Depression
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Disorientation
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Depression suicidal
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Intentional self-injury
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hallucination
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Major depression
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Personality change due to a general medical condition
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Mental status changes
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Psychiatric decompensation
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Restlessness
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Suicidal ideation
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Product issues
|
|
|
Device breakage
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Device dislocation
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Device defective
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Device failure
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Device occlusion
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Device fastener issue
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Device malfunction
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lead dislodgement
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hepatobiliary disorders
|
|
|
Acute hepatic failure
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Autoimmune hepatitis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Bile duct stenosis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Bile duct stone
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Biliary colic
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Biliary cyst
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Biliary dilatation
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Biliary dyspepsia
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cholangitis acute
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cholecystitis acute
|
|
|
subjects affected / exposed
|
6 / 2816 (0.21%) |
9 / 2820 (0.32%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 9 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cholecystitis
|
|
|
subjects affected / exposed
|
9 / 2816 (0.32%) |
4 / 2820 (0.14%) |
occurrences causally related to treatment / all
|
0 / 10 |
1 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cholelithiasis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
4 / 2820 (0.14%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Drug-induced liver injury
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
1 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hepatic failure
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hepatic cirrhosis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
Hepatic mass
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hepatic pain
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hepatitis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hepatitis acute
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ischaemic hepatitis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Jaundice cholestatic
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Investigations
|
|
|
Angiocardiogram
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Anticoagulation drug level above therapeutic
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Biopsy bladder
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Biopsy prostate
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Blood creatinine increased
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
1 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
1 / 1 |
0 / 0 |
Blood glucose increased
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Blood glucose fluctuation
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cardiac output decreased
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Blood sodium decreased
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cardiac ventriculogram
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Coagulation test abnormal
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ejection fraction
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ejection fraction abnormal
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ejection fraction decreased
|
|
|
subjects affected / exposed
|
12 / 2816 (0.43%) |
6 / 2820 (0.21%) |
occurrences causally related to treatment / all
|
0 / 12 |
0 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Electrocardiogram QT prolonged
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Glycosylated haemoglobin increased
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Heart rate decreased
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Haemoglobin decreased
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hepatic enzyme increased
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Influenza B virus test positive
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
International normalised ratio increased
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Liver function test abnormal
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
1 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Liver function test increased
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Neutrophil count decreased
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Occult blood positive
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Renal function test abnormal
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
SARS-CoV-2 test positive
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Scan myocardial perfusion abnormal
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Transaminases increased
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Stress echocardiogram
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Troponin increased
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Weight increased
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Weight decreased
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Injury, poisoning and procedural complications
|
|
|
Acetabulum fracture
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Accidental exposure to product
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Anaemia postoperative
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Anastomotic leak
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ankle fracture
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Arterial bypass occlusion
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Arterial injury
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cardiac function disturbance postoperative
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Cardiac procedure complication
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cardiac valve rupture
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cervical vertebral fracture
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Chest injury
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Clavicle fracture
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Concussion
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Contusion
|
|
|
subjects affected / exposed
|
5 / 2816 (0.18%) |
4 / 2820 (0.14%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Coronary artery restenosis
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Coronary bypass thrombosis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Coronary vascular graft occlusion
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Craniocerebral injury
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Electric shock
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Fall
|
|
|
subjects affected / exposed
|
7 / 2816 (0.25%) |
5 / 2820 (0.18%) |
occurrences causally related to treatment / all
|
0 / 7 |
2 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Femur fracture
|
|
|
subjects affected / exposed
|
4 / 2816 (0.14%) |
4 / 2820 (0.14%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Femoral neck fracture
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Fibula fracture
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Foot fracture
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Foreign body in gastrointestinal tract
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Fracture
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Fracture displacement
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hand fracture
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hip fracture
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Head injury
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Humerus fracture
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Incisional hernia
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Intentional overdose
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Jaw fracture
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Joint dislocation
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 7 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Limb injury
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lower limb fracture
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lumbar vertebral fracture
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Muscle injury
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Muscle rupture
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Periorbital haemorrhage
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Overdose
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pneumothorax traumatic
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Periprocedural myocardial infarction
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Poisoning
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Post intensive care syndrome
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Post procedural discharge
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Post procedural complication
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Post procedural fistula
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Post procedural haematuria
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Post procedural haemorrhage
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
4 / 2820 (0.14%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Post procedural myocardial infarction
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Post procedural urine leak
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Prevertebral soft tissue swelling of cervical space
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Procedural haemorrhage
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Procedural complication
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pulmonary contusion
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Rib fracture
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Radius fracture
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Road traffic accident
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Skin laceration
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Skin abrasion
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Spinal compression fracture
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Splenic rupture
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Sternal fracture
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Stomal hernia
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Subcutaneous haematoma
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Subdural haematoma
|
|
|
subjects affected / exposed
|
4 / 2816 (0.14%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Subdural haemorrhage
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Thermal burn
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Toxicity to various agents
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Thoracic vertebral fracture
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Traumatic intracranial haemorrhage
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Upper limb fracture
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Vascular pseudoaneurysm
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Vasoplegia syndrome
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Wound dehiscence
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Wrist fracture
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Congenital, familial and genetic disorders
|
|
|
Ventricular septal defect
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cardiac disorders
|
|
|
Acute coronary syndrome
|
|
|
subjects affected / exposed
|
13 / 2816 (0.46%) |
11 / 2820 (0.39%) |
occurrences causally related to treatment / all
|
1 / 14 |
0 / 11 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Acute left ventricular failure
|
|
|
subjects affected / exposed
|
6 / 2816 (0.21%) |
9 / 2820 (0.32%) |
occurrences causally related to treatment / all
|
1 / 6 |
0 / 9 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
Acute myocardial infarction
|
|
|
subjects affected / exposed
|
95 / 2816 (3.37%) |
92 / 2820 (3.26%) |
occurrences causally related to treatment / all
|
0 / 101 |
1 / 100 |
deaths causally related to treatment / all
|
0 / 13 |
0 / 8 |
Adams-Stokes syndrome
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Angina pectoris
|
|
|
subjects affected / exposed
|
84 / 2816 (2.98%) |
59 / 2820 (2.09%) |
occurrences causally related to treatment / all
|
0 / 91 |
0 / 69 |
deaths causally related to treatment / all
|
0 / 4 |
0 / 2 |
Angina unstable
|
|
|
subjects affected / exposed
|
76 / 2816 (2.70%) |
65 / 2820 (2.30%) |
occurrences causally related to treatment / all
|
0 / 89 |
0 / 70 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Anginal equivalent
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Aortic valve incompetence
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Aortic valve disease
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Aortic valve stenosis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Arrhythmia
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
9 / 2820 (0.32%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 10 |
deaths causally related to treatment / all
|
0 / 3 |
0 / 6 |
Arteriosclerosis coronary artery
|
|
|
subjects affected / exposed
|
5 / 2816 (0.18%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Atrial fibrillation
|
|
|
subjects affected / exposed
|
22 / 2816 (0.78%) |
30 / 2820 (1.06%) |
occurrences causally related to treatment / all
|
0 / 26 |
0 / 32 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Atrial flutter
|
|
|
subjects affected / exposed
|
7 / 2816 (0.25%) |
6 / 2820 (0.21%) |
occurrences causally related to treatment / all
|
0 / 7 |
0 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Atrial tachycardia
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Atrioventricular block
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
5 / 2820 (0.18%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Atrioventricular block complete
|
|
|
subjects affected / exposed
|
4 / 2816 (0.14%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Atrioventricular block second degree
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Bradycardia
|
|
|
subjects affected / exposed
|
4 / 2816 (0.14%) |
6 / 2820 (0.21%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 6 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Cardiac aneurysm
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Cardiac arrest
|
|
|
subjects affected / exposed
|
31 / 2816 (1.10%) |
24 / 2820 (0.85%) |
occurrences causally related to treatment / all
|
0 / 32 |
0 / 27 |
deaths causally related to treatment / all
|
0 / 18 |
0 / 13 |
Cardiac asthma
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cardiac discomfort
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cardiac disorder
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cardiac failure
|
|
|
subjects affected / exposed
|
183 / 2816 (6.50%) |
149 / 2820 (5.28%) |
occurrences causally related to treatment / all
|
4 / 249 |
4 / 219 |
deaths causally related to treatment / all
|
1 / 18 |
0 / 18 |
Cardiac failure acute
|
|
|
subjects affected / exposed
|
22 / 2816 (0.78%) |
28 / 2820 (0.99%) |
occurrences causally related to treatment / all
|
1 / 33 |
0 / 33 |
deaths causally related to treatment / all
|
0 / 4 |
0 / 3 |
Cardiac failure chronic
|
|
|
subjects affected / exposed
|
8 / 2816 (0.28%) |
12 / 2820 (0.43%) |
occurrences causally related to treatment / all
|
0 / 10 |
0 / 13 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Cardiac failure congestive
|
|
|
subjects affected / exposed
|
37 / 2816 (1.31%) |
27 / 2820 (0.96%) |
occurrences causally related to treatment / all
|
2 / 54 |
0 / 33 |
deaths causally related to treatment / all
|
1 / 7 |
0 / 3 |
Cardiac perforation
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cardiac tamponade
|
|
|
subjects affected / exposed
|
6 / 2816 (0.21%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 3 |
0 / 0 |
Cardiac ventricular thrombosis
|
|
|
subjects affected / exposed
|
8 / 2816 (0.28%) |
4 / 2820 (0.14%) |
occurrences causally related to treatment / all
|
0 / 9 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
Cardio-respiratory arrest
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
7 / 2820 (0.25%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 5 |
Cardiogenic shock
|
|
|
subjects affected / exposed
|
12 / 2816 (0.43%) |
17 / 2820 (0.60%) |
occurrences causally related to treatment / all
|
1 / 12 |
0 / 18 |
deaths causally related to treatment / all
|
1 / 11 |
0 / 6 |
Cardiomyopathy
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cardiopulmonary failure
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Cardiovascular disorder
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
Cardiovascular insufficiency
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
Congestive cardiomyopathy
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Chronic left ventricular failure
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Coronary artery insufficiency
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Coronary artery disease
|
|
|
subjects affected / exposed
|
30 / 2816 (1.07%) |
23 / 2820 (0.82%) |
occurrences causally related to treatment / all
|
0 / 30 |
0 / 24 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
Coronary artery occlusion
|
|
|
subjects affected / exposed
|
6 / 2816 (0.21%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Coronary artery perforation
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Coronary artery stenosis
|
|
|
subjects affected / exposed
|
4 / 2816 (0.14%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Dressler's syndrome
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Endocarditis noninfective
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Intracardiac thrombus
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ischaemic cardiomyopathy
|
|
|
subjects affected / exposed
|
10 / 2816 (0.36%) |
6 / 2820 (0.21%) |
occurrences causally related to treatment / all
|
0 / 10 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Left ventricular dysfunction
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Left ventricular failure
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Microvascular coronary artery disease
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Mitral valve incompetence
|
|
|
subjects affected / exposed
|
4 / 2816 (0.14%) |
5 / 2820 (0.18%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Myocardial fibrosis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Myocardial infarction
|
|
|
subjects affected / exposed
|
44 / 2816 (1.56%) |
51 / 2820 (1.81%) |
occurrences causally related to treatment / all
|
1 / 47 |
0 / 51 |
deaths causally related to treatment / all
|
0 / 9 |
0 / 18 |
Myocardial ischaemia
|
|
|
subjects affected / exposed
|
9 / 2816 (0.32%) |
9 / 2820 (0.32%) |
occurrences causally related to treatment / all
|
0 / 9 |
0 / 10 |
deaths causally related to treatment / all
|
0 / 4 |
0 / 1 |
Palpitations
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
4 / 2820 (0.14%) |
occurrences causally related to treatment / all
|
0 / 1 |
1 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Papillary muscle disorder
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Paroxysmal atrioventricular block
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pericardial effusion
|
|
|
subjects affected / exposed
|
6 / 2816 (0.21%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 7 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pericardial haemorrhage
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pericarditis
|
|
|
subjects affected / exposed
|
8 / 2816 (0.28%) |
6 / 2820 (0.21%) |
occurrences causally related to treatment / all
|
0 / 8 |
0 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pulseless electrical activity
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Sinus bradycardia
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Sinus node dysfunction
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Supraventricular tachycardia
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ventricle rupture
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Tachycardia
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ventricular arrhythmia
|
|
|
subjects affected / exposed
|
5 / 2816 (0.18%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Ventricular dysfunction
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ventricular extrasystoles
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ventricular fibrillation
|
|
|
subjects affected / exposed
|
11 / 2816 (0.39%) |
12 / 2820 (0.43%) |
occurrences causally related to treatment / all
|
0 / 11 |
0 / 12 |
deaths causally related to treatment / all
|
0 / 4 |
0 / 5 |
Ventricular remodelling
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ventricular tachyarrhythmia
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ventricular tachycardia
|
|
|
subjects affected / exposed
|
23 / 2816 (0.82%) |
19 / 2820 (0.67%) |
occurrences causally related to treatment / all
|
0 / 26 |
0 / 19 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
Nervous system disorders
|
|
|
Arachnoid cyst
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ataxia
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Brain stem ischaemia
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Carotid artery occlusion
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Carotid artery stenosis
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
5 / 2820 (0.18%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cerebellar infarction
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cerebral haemorrhage
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cerebral infarction
|
|
|
subjects affected / exposed
|
9 / 2816 (0.32%) |
8 / 2820 (0.28%) |
occurrences causally related to treatment / all
|
0 / 9 |
0 / 9 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
Cerebral hypoperfusion
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cerebral ischaemia
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cerebral venous sinus thrombosis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cerebrovascular accident
|
|
|
subjects affected / exposed
|
33 / 2816 (1.17%) |
32 / 2820 (1.13%) |
occurrences causally related to treatment / all
|
0 / 38 |
0 / 36 |
deaths causally related to treatment / all
|
0 / 3 |
0 / 5 |
Cerebrovascular insufficiency
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cerebrovascular disorder
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cervical radiculopathy
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cervicobrachial syndrome
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Disturbance in attention
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Demyelinating polyneuropathy
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Dizziness
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
7 / 2820 (0.25%) |
occurrences causally related to treatment / all
|
1 / 3 |
3 / 8 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Dizziness postural
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Dysarthria
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Embolic stroke
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Encephalopathy
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Epilepsy
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Facial paralysis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Generalised tonic-clonic seizure
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Haemorrhage intracranial
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Haemorrhagic stroke
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 2 |
Haemorrhagic transformation stroke
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Headache
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Hemianopia
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypoaesthesia
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hemiparesis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypoglycaemic coma
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypoxic-ischaemic encephalopathy
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Irregular sleep wake rhythm disorder
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Ischaemic stroke
|
|
|
subjects affected / exposed
|
15 / 2816 (0.53%) |
12 / 2820 (0.43%) |
occurrences causally related to treatment / all
|
0 / 15 |
1 / 12 |
deaths causally related to treatment / all
|
0 / 4 |
0 / 0 |
Lacunar stroke
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lacunar infarction
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Loss of consciousness
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Metabolic encephalopathy
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Migraine
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Moyamoya disease
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Neuropathy peripheral
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Paraesthesia
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Polyneuropathy
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Partial seizures
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Post stroke seizure
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Radiculopathy
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Presyncope
|
|
|
subjects affected / exposed
|
4 / 2816 (0.14%) |
9 / 2820 (0.32%) |
occurrences causally related to treatment / all
|
0 / 4 |
2 / 9 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Psychogenic seizure
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Sciatica
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Seizure
|
|
|
subjects affected / exposed
|
6 / 2816 (0.21%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Spinal cord haemorrhage
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Subarachnoid haemorrhage
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Status epilepticus
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Subdural hygroma
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Vertebrobasilar insufficiency
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Syncope
|
|
|
subjects affected / exposed
|
30 / 2816 (1.07%) |
36 / 2820 (1.28%) |
occurrences causally related to treatment / all
|
4 / 31 |
9 / 43 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Transient ischaemic attack
|
|
|
subjects affected / exposed
|
10 / 2816 (0.36%) |
9 / 2820 (0.32%) |
occurrences causally related to treatment / all
|
0 / 11 |
0 / 10 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Blood and lymphatic system disorders
|
|
|
Anaemia macrocytic
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Anaemia
|
|
|
subjects affected / exposed
|
23 / 2816 (0.82%) |
30 / 2820 (1.06%) |
occurrences causally related to treatment / all
|
0 / 25 |
0 / 31 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Blood loss anaemia
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Anaemia vitamin B12 deficiency
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Eosinophilia
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Febrile neutropenia
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypochromic anaemia
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypocoagulable state
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Immune thrombocytopenia
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Iron deficiency anaemia
|
|
|
subjects affected / exposed
|
4 / 2816 (0.14%) |
7 / 2820 (0.25%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Leukocytosis
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Leukopenia
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lymphadenopathy
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Microcytic anaemia
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Normocytic anaemia
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pancytopenia
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Splenic haemorrhage
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ear and labyrinth disorders
|
|
|
Vertigo positional
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Vertigo
|
|
|
subjects affected / exposed
|
5 / 2816 (0.18%) |
4 / 2820 (0.14%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Vestibular disorder
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Eye disorders
|
|
|
Arteriosclerotic retinopathy
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Blindness unilateral
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Eye oedema
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cataract
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Diplopia
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Glaucoma
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Eye swelling
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Iridocyclitis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Intraocular haematoma
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Keratitis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Open angle glaucoma
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Optic ischaemic neuropathy
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Periorbital oedema
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Retinal detachment
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Vitreous haemorrhage
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Rhegmatogenous retinal detachment
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Visual impairment
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastrointestinal disorders
|
|
|
Abdominal discomfort
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Abdominal hernia
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Abdominal mass
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Abdominal hernia obstructive
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Abdominal pain
|
|
|
subjects affected / exposed
|
5 / 2816 (0.18%) |
8 / 2820 (0.28%) |
occurrences causally related to treatment / all
|
1 / 5 |
0 / 8 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Abdominal pain upper
|
|
|
subjects affected / exposed
|
5 / 2816 (0.18%) |
7 / 2820 (0.25%) |
occurrences causally related to treatment / all
|
1 / 5 |
0 / 9 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Colitis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Ascites
|
|
|
subjects affected / exposed
|
4 / 2816 (0.14%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
1 / 4 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Acute abdomen
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Colitis ischaemic
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Constipation
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Crohn's disease
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Dental cyst
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Diarrhoea
|
|
|
subjects affected / exposed
|
8 / 2816 (0.28%) |
4 / 2820 (0.14%) |
occurrences causally related to treatment / all
|
0 / 8 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Diarrhoea haemorrhagic
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Diverticular perforation
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Diverticulum intestinal
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Diverticulum intestinal haemorrhagic
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Duodenal ulcer
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Duodenal ulcer haemorrhage
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Dyspepsia
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Dysphagia
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Enteritis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Enterocolitis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Faeces discoloured
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Food poisoning
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastric haemorrhage
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastric ulcer
|
|
|
subjects affected / exposed
|
5 / 2816 (0.18%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastric ulcer haemorrhage
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastritis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastritis erosive
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastritis haemorrhagic
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Gastrointestinal haemorrhage
|
|
|
subjects affected / exposed
|
12 / 2816 (0.43%) |
15 / 2820 (0.53%) |
occurrences causally related to treatment / all
|
0 / 12 |
0 / 16 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 1 |
Gastrointestinal disorder
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastrooesophageal reflux disease
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
4 / 2820 (0.14%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Haematemesis
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Haematochezia
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Haemorrhoidal haemorrhage
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Haemorrhoids
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Haemorrhoids thrombosed
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ileus
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ileus paralytic
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Impaired gastric emptying
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Inguinal hernia
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
5 / 2820 (0.18%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Intestinal haemorrhage
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Intestinal ischaemia
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Intestinal obstruction
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Intestinal pseudo-obstruction
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Large intestine perforation
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Large intestinal obstruction
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Large intestine polyp
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lip swelling
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Mechanical ileus
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Malabsorption
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lower gastrointestinal haemorrhage
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Melaena
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
7 / 2820 (0.25%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Mouth swelling
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Mesenteric arterial occlusion
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Nausea
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
5 / 2820 (0.18%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pancreatitis acute
|
|
|
subjects affected / exposed
|
5 / 2816 (0.18%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Pancreatitis
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Oesophageal achalasia
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Peritoneal adhesions
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Peptic ulcer
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Rectal haemorrhage
|
|
|
subjects affected / exposed
|
6 / 2816 (0.21%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Rectal polyp
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Retroperitoneal haemorrhage
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Small intestinal obstruction
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Umbilical hernia
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Upper gastrointestinal haemorrhage
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Volvulus
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Vomiting
|
|
|
subjects affected / exposed
|
5 / 2816 (0.18%) |
5 / 2820 (0.18%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Skin and subcutaneous tissue disorders
|
|
|
Angioedema
|
|
|
subjects affected / exposed
|
5 / 2816 (0.18%) |
4 / 2820 (0.14%) |
occurrences causally related to treatment / all
|
5 / 5 |
4 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Decubitus ulcer
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Dermatitis allergic
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Diabetic foot
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
6 / 2820 (0.21%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 8 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Diabetic wound
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Eczema
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Rash
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pruritus
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hyperhidrosis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Rash maculo-papular
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Symmetrical drug-related intertriginous and flexural exanthema
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Skin ulcer
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Urticaria
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Renal and urinary disorders
|
|
|
Acute kidney injury
|
|
|
subjects affected / exposed
|
30 / 2816 (1.07%) |
37 / 2820 (1.31%) |
occurrences causally related to treatment / all
|
12 / 36 |
12 / 40 |
deaths causally related to treatment / all
|
0 / 0 |
2 / 3 |
Anuria
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Azotaemia
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Bladder tamponade
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Chronic kidney disease
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
5 / 2820 (0.18%) |
occurrences causally related to treatment / all
|
0 / 1 |
1 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Calculus bladder
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Dysuria
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Haematuria
|
|
|
subjects affected / exposed
|
7 / 2816 (0.25%) |
9 / 2820 (0.32%) |
occurrences causally related to treatment / all
|
0 / 9 |
0 / 14 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
End stage renal disease
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Haemorrhage urinary tract
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Nephrolithiasis
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hydronephrosis
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Nephrotic syndrome
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Renal colic
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Renal failure
|
|
|
subjects affected / exposed
|
8 / 2816 (0.28%) |
10 / 2820 (0.35%) |
occurrences causally related to treatment / all
|
2 / 8 |
2 / 11 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 4 |
Renal haematoma
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Renal impairment
|
|
|
subjects affected / exposed
|
6 / 2816 (0.21%) |
14 / 2820 (0.50%) |
occurrences causally related to treatment / all
|
3 / 6 |
7 / 15 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Ureteric obstruction
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ureteric stenosis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ureterolithiasis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Urethral stenosis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Urethral obstruction
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Urinary bladder polyp
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Urinary retention
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
6 / 2820 (0.21%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Endocrine disorders
|
|
|
Adrenal mass
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hyperthyroidism
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Musculoskeletal and connective tissue disorders
|
|
|
Arthritis reactive
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Arthralgia
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
4 / 2820 (0.14%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Arthritis
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Bursitis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Back disorder
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Back pain
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Deformity thorax
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Costochondritis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Chondrocalcinosis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gouty arthritis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Enthesopathy
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Fistula discharge
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Haemarthrosis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Intervertebral disc degeneration
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Intervertebral disc disorder
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Intervertebral disc protrusion
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Muscular weakness
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lumbar spinal stenosis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Mobility decreased
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Musculoskeletal chest pain
|
|
|
subjects affected / exposed
|
5 / 2816 (0.18%) |
5 / 2820 (0.18%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Musculoskeletal pain
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Myalgia
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Osteitis
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Osteoarthritis
|
|
|
subjects affected / exposed
|
6 / 2816 (0.21%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Osteochondrosis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Osteoporotic fracture
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pain in extremity
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pathological fracture
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Polyarthritis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Periostosis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Polymyalgia rheumatica
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pseudarthrosis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Rhabdomyolysis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Spinal osteoarthritis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Infections and infestations
|
|
|
Abscess
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Abscess jaw
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Abscess limb
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Abscess oral
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Appendicitis
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Anal abscess
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Bacteraemia
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Bacterial abdominal infection
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Bacterial sepsis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Biliary sepsis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Bacterial infection
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Bronchitis
|
|
|
subjects affected / exposed
|
6 / 2816 (0.21%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Bone abscess
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
COVID-19
|
|
|
subjects affected / exposed
|
16 / 2816 (0.57%) |
13 / 2820 (0.46%) |
occurrences causally related to treatment / all
|
0 / 16 |
0 / 13 |
deaths causally related to treatment / all
|
0 / 4 |
0 / 5 |
COVID-19 pneumonia
|
|
|
subjects affected / exposed
|
8 / 2816 (0.28%) |
6 / 2820 (0.21%) |
occurrences causally related to treatment / all
|
0 / 8 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 4 |
0 / 2 |
Carbuncle
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cellulitis
|
|
|
subjects affected / exposed
|
5 / 2816 (0.18%) |
11 / 2820 (0.39%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 12 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Cholangitis infective
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Clostridium difficile infection
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Coronavirus infection
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
4 / 2820 (0.14%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 2 |
Cystitis
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
7 / 2820 (0.25%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Device related infection
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Diabetic foot infection
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Diabetic gangrene
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Diarrhoea infectious
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Diverticulitis
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Endocarditis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 2 |
Empyema
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Endometritis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Endocarditis staphylococcal
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Epididymitis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Erysipelas
|
|
|
subjects affected / exposed
|
5 / 2816 (0.18%) |
6 / 2820 (0.21%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Escherichia sepsis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Escherichia bacteraemia
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Escherichia urinary tract infection
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Fournier's gangrene
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Gangrene
|
|
|
subjects affected / exposed
|
5 / 2816 (0.18%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gas gangrene
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastroenteritis
|
|
|
subjects affected / exposed
|
7 / 2816 (0.25%) |
11 / 2820 (0.39%) |
occurrences causally related to treatment / all
|
0 / 7 |
0 / 12 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastroenteritis viral
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gastrointestinal infection
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Genital herpes
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Haematoma infection
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Helicobacter duodenal ulcer
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Implant site infection
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Incision site abscess
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Infected dermal cyst
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Infected skin ulcer
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Infection
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
4 / 2820 (0.14%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Infective exacerbation of chronic obstructive airways disease
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Influenza
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Joint abscess
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Liver abscess
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Labyrinthitis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Localised infection
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lung abscess
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lower respiratory tract infection
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
4 / 2820 (0.14%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Meningitis bacterial
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Necrotising fasciitis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Neutropenic sepsis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Oral candidiasis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Osteomyelitis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
4 / 2820 (0.14%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Orchitis
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Osteomyelitis acute
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Otitis externa
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Otitis media
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Parotitis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Peritonitis
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Pharyngeal abscess
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pharyngotonsillitis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pneumonia
|
|
|
subjects affected / exposed
|
73 / 2816 (2.59%) |
61 / 2820 (2.16%) |
occurrences causally related to treatment / all
|
0 / 79 |
0 / 65 |
deaths causally related to treatment / all
|
0 / 8 |
0 / 7 |
Pneumonia bacterial
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pneumonia mycoplasmal
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pneumonia pneumococcal
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pneumonia viral
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pneumonia staphylococcal
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pulmonary tuberculosis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Postoperative wound infection
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Post procedural sepsis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Pyelonephritis
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pyelonephritis acute
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pyelonephritis chronic
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Respiratory tract infection
|
|
|
subjects affected / exposed
|
6 / 2816 (0.21%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
1 / 7 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
Respiratory tract infection viral
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Rhinovirus infection
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Scrotal abscess
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Sepsis
|
|
|
subjects affected / exposed
|
13 / 2816 (0.46%) |
19 / 2820 (0.67%) |
occurrences causally related to treatment / all
|
0 / 13 |
0 / 24 |
deaths causally related to treatment / all
|
0 / 7 |
0 / 7 |
Septic shock
|
|
|
subjects affected / exposed
|
8 / 2816 (0.28%) |
9 / 2820 (0.32%) |
occurrences causally related to treatment / all
|
0 / 8 |
0 / 9 |
deaths causally related to treatment / all
|
0 / 4 |
0 / 4 |
Skin infection
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Staphylococcal sepsis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Staphylococcal bacteraemia
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Tooth abscess
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Suspected COVID-19
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Urinary tract infection
|
|
|
subjects affected / exposed
|
16 / 2816 (0.57%) |
28 / 2820 (0.99%) |
occurrences causally related to treatment / all
|
0 / 17 |
0 / 33 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Upper respiratory tract infection
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Vestibular neuronitis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Urosepsis
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
6 / 2820 (0.21%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Viral labyrinthitis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Viral sepsis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Wound abscess
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Wound infection
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Wound infection bacterial
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Metabolism and nutrition disorders
|
|
|
Acidosis hyperchloraemic
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Decreased appetite
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Dehydration
|
|
|
subjects affected / exposed
|
10 / 2816 (0.36%) |
9 / 2820 (0.32%) |
occurrences causally related to treatment / all
|
0 / 10 |
1 / 9 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
Cachexia
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
Diabetes mellitus inadequate control
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Diabetic ketoacidosis
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Diabetic metabolic decompensation
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Diabetes mellitus
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Euglycaemic diabetic ketoacidosis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Fluid overload
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Electrolyte imbalance
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Gout
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypercalcaemia
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Food intolerance
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hyperkalaemia
|
|
|
subjects affected / exposed
|
4 / 2816 (0.14%) |
15 / 2820 (0.53%) |
occurrences causally related to treatment / all
|
2 / 4 |
12 / 20 |
deaths causally related to treatment / all
|
1 / 1 |
0 / 0 |
Hypertriglyceridaemia
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hyperglycaemia
|
|
|
subjects affected / exposed
|
4 / 2816 (0.14%) |
6 / 2820 (0.21%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypokalaemia
|
|
|
subjects affected / exposed
|
3 / 2816 (0.11%) |
5 / 2820 (0.18%) |
occurrences causally related to treatment / all
|
1 / 3 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypervolaemia
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypoglycaemia
|
|
|
subjects affected / exposed
|
10 / 2816 (0.36%) |
7 / 2820 (0.25%) |
occurrences causally related to treatment / all
|
1 / 11 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypovolaemia
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hyponatraemia
|
|
|
subjects affected / exposed
|
4 / 2816 (0.14%) |
3 / 2820 (0.11%) |
occurrences causally related to treatment / all
|
1 / 4 |
1 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Hypophosphataemia
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Malnutrition
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Lactic acidosis
|
|
|
subjects affected / exposed
|
2 / 2816 (0.07%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Ketoacidosis
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Pseudohyponatraemia
|
|
|
subjects affected / exposed
|
0 / 2816 (0.00%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Type 2 diabetes mellitus
|
|
|
subjects affected / exposed
|
4 / 2816 (0.14%) |
0 / 2820 (0.00%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Obesity
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
1 / 2820 (0.04%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
Metabolic acidosis
|
|
|
subjects affected / exposed
|
1 / 2816 (0.04%) |
2 / 2820 (0.07%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |